Provided by Tiger Trade Technology Pte. Ltd.

AKESO

108.700
+2.4002.26%
Volume:16.11M
Turnover:1.72B
Market Cap:100.11B
PE:-88.18
High:109.900
Open:102.100
Low:101.000
Close:106.300
52wk High:156.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:1.39
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.233
ROE:-13.59%
ROA:-4.57%
PB:10.10
PE(LYR):-88.18
PS:24.84

Loading ...

Loose Fed Bets and AI Monetization Fuel Hong Kong Stocks Rally

Stock News
·
Sep 04

Daiwa Highlights AKESO's HARMONi-2 Milestone, Bolstering Case for Global NSCLC Study Success

Stock News
·
Sep 04

Movement Alert|AKESO Rises 5.73% in Regular Trading, Ivonescimab HARMONi-2 Study Achieves OS Key Secondary Endpoint Versus Keytruda

Market Focus
·
Sep 04

Akeso Reports Stable Share Capital in August 2026; Minor Decline in Outstanding Options

Bulletin Express
·
Sep 03

Movement Alert|AKESO Rises 5.3% in Regular Trading, Ivonescimab HARMONi-2 Study Achieves OS Key Secondary Endpoint

Market Focus
·
Sep 03

Akeso: Ivonescimab Shows Significant Overall-Survival Gain Versus Pembrolizumab in Phase III HARMONI-2 Trial

Bulletin Express
·
Sep 03

Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study

THOMSON REUTERS
·
Sep 03

Akeso Says Ivonescimab Meets Overall Survival Endpoint in Phase III HARMONi-2 Lung Cancer Trial

Reuters
·
Sep 03

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line Pd-L1-Positive Nsclc

THOMSON REUTERS
·
Sep 03

Akeso - Ivonescimab Demonstrates Statistically Significant Improvement over Pembrolizumab

THOMSON REUTERS
·
Sep 03

Movement Alert|AKESO Falls 3.06% in Regular Trading, Interim Earnings Miss and Bispecific Antibody Controversy Continue to Weigh

Market Focus
·
Sep 01

Movement Alert|AKESO Falls 3.15% in Regular Trading, H1 Earnings Miss Expectations Amid Ongoing Bispecific Antibody Concerns

Market Focus
·
Aug 31

Akeso, Inc. (HKG:9926) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Simply Wall St.
·
Aug 31

Akeso Says Phase III Ivonescimab-Chemo Trial in Biliary Tract Cancer Meets Overall Survival Endpoint

Reuters
·
Aug 28

Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

Dow Jones
·
Aug 28

Movement Alert|AKESO Falls 6.32% in Regular Trading, Profit-Taking After H1 Results Still Show Loss Despite 28% Revenue Growth

Market Focus
·
Aug 28

Akeso's Losses Narrow in H1 as Revenue Climbs 28%

MT Newswires Live
·
Aug 28

Akeso Interim 2026 Results: Revenue Reaches RMB 1.81 Billion, Net Loss Narrows by 24.0%

Bulletin Express
·
Aug 27

Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion

Reuters
·
Aug 27

Akeso Surges Over 6% Intraday as Guosen Securities Initiates 'Outperform' Rating

Deep News
·
Aug 27